Adaptin Bio, Inc.
APTN- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001938571
No open-market purchases or sales by Adaptin Bio, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Adaptin Bio, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Adaptin Bio, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Pedder Simon | Executive Chairman | – | Sep 10, 2025 | 0 |
| Riehle J Nick | Director | – | Sep 10, 2025 | 0 |
| Hewitt L Arthur | Chief Development Officer | – | Sep 10, 2025 | 0 |
| Roberts Michael J | President and CEO | – | Sep 10, 2025 | 0 |
| Zook Anthony P. | Director | – | Sep 10, 2025 | 0 |
| Gallagher Patrick Joseph | Director | – | Sep 10, 2025 | 0 |
| Maness Timothy | Chief Financial Officer | – | Sep 10, 2025 | 0 |
| Lucius Partners LLC | 10% Owner | 3,250,000 | Feb 13, 2025 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
No insider trades match these filters.